Brian Huber, a former executive at GlaxoSmithKline, is the new chief scientific officer at Adherex technologies.

Huber was vice president of biology and pharmacology in drug discovery at GSK. He directed several departments, including Metabolic Diseases, Molecular Pharmacology & Endocrinology, Biochemical & Analytical Pharmacology, Virology and International Clinical Virology.

“Following the successful completion of two financings, one of my primary objectives for this year has been to recruit a seasoned executive team for Adherex,” said William Peters, chairman and CEO of Adherex, in a statement. “With Dr. Huber’s appointment, this goal has been achieved. I believe that Adherex now has the scientific, clinical and administrative leadership in place to advance our preclinical and clinical drug candidates, and the administrative and business expertise to build shareholder value.”

Orest Blaschuk, co-founder of Adherex, is chief scientist.

Adherex is seeking to develop cancer therapies.

Huber has also served as vice president of pharmacology for GlaxoWellcome, with responsibility for the departments of cancer biology, musculoskeletal diseases, metabolic diseases and virology.